TOKYO, Mar 23 (Pulse News Wire) – Shionogi & CO.,LTD. (4507.T) secured a bridge loan related to its acquisition of Edaravone treatment businesses from Daiichi Pharmaceuticals.
The loan agreement was finalized on March 24, 2026 and the funds will be disbursed on March 27, 2026. Key details of the loan include: - Borrowing entity: Sumitomo Mitsui Banking Corporation - Amount borrowed: ¥360.0 billion - Interest rate: Benchmark rate plus spread - Final repayment date: March 26, 2027 - No collateral required Regarding future plans, Shionogi intends to refinance the debt with long-term funding prior to the final repayment date.
Impact on earnings is expected to be minor for the fiscal year ending March 2026. An assessment for the fiscal year ending March 2027 is ongoing; any significant developments will be disclosed promptly.
🟢 Confidence: High AI-translated content.